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Abstract
Background: Point-of-care testing for creatinine using a fin-
gerprick sample and resultant estimated glomerular filtration
rate has potential for screening for chronic kidney disease in
community settings. This study assessed the applicability of
the Nova StatSensor creatinine analyzer for this purpose.
Methods: Fingerprick samples from 100 patients (63 renal,
37 healthy volunteers; range 46–962 mmol/L) were assayed
using two StatSensor analyzers. Lithium heparin venous
plasma samples collected simultaneously were assayed in
duplicate using the isotope dilution mass spectrometry-
aligned Roche Creatinine Plus enzymatic assay on a Hitachi
Modular P unit. Method comparison statistics and the ability
of the StatSensor to correctly categorise estimated glomeru-
lar filtration rate above or below 60 mL/min were calculated
pre- and post-alignment with the laboratory method.
Results: StatSensor 1 creatinine results (y) were much lower
than the laboratory (ys0.75xq10.2, average bias –47.3,
95% limits of agreement –208 to q113 mmol/L). For esti-
mated glomerular filtration rates above or below 60 mL/min,
100% and 87% of results respectively agreed with the lab-
oratory estimated glomerular filtration rate (79% and 96%
post-alignment). StatSensor 2 statistics were similar. The
95% limits of agreement between StatSensor creatinine
results were –35 to q34 mmol/L.
Conclusions: Isotope dilution mass spectrometry alignment
of the StatSensor will identify most patients with estimated
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glomerular filtration rate -60 mL/min, but there will be
many falsely low estimated glomerular filtration rate results
that require laboratory validation. Creatinine results need
improvement.
Clin Chem Lab Med 2010;48:1113–9.
Keywords: chronic kidney disease; creatinine; estimated
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Introduction
Chronic kidney disease (CKD) has a prevalence of approx-
imately 16% and 13% in Australian and American environ-
ments, respectively (1, 2). The disease is usually silent and
progressive, and end-stage renal disease is placing increasing
burdens on health care budgets, with increasing numbers of
patients requiring dialysis (3). Early signs of CKD include
proteinuria, increased blood pressure and reduced glomerular
filtration rate (GFR) (4). GFR can be estimated (eGFR) using
laboratory measurements of serum creatinine, and consider-
able international efforts have been made to align creatinine
results to isotope dilution mass spectrometry (IDMS) equiv-
alent standards (5). In addition, simplified equations to con-
vert serum creatinine results to eGFR based on age, gender,
and ethnic background have now been adopted (5–7).
Although efforts to align the calibration of laboratory cre-
atinine estimations are well-advanced (8), there can be valid
reasons for measuring creatinine in non-laboratory situations.
These include screening programs for CKD to facilitate the
early detection and follow-up of at-risk patients. Recently,
Kidney Health Australia conducted a targeted community-
based program for CKD risk called Kidney Evaluation for
You (KEY). This pilot program was the first program for
CKD risk assessment undertaken in the primary health care
setting in Australia (9). The KEY study used the i-STAT
point-of-care testing (POCT) analyzer (Abbott Point-of-Care
Inc., Princeton, NJ, USA) for measuring creatinine, with sub-
sequent calculation of eGFR. However, the i-STAT device
required a venous whole blood sample of approximately
100 mL, which is less ideal than a fingerprick sample for a
screening situation. In addition, i-STAT has been reported to
produce higher creatinine results than the Roche enzymatic
creatinine assay (Roche Diagnostics, Sydney, Australia) (10).
A recently released point-of-care device from Nova Bio-
medical (Waltham, MA, USA) that measures creatinine using
just 1.2 mL of whole blood and converts creatinine results
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Table 1 Nova StatSensor day-to-day method imprecision (ns20).
QC Target Acceptable Mean SD CV% Range
range
Device 1 Device 2 Device 1 Device 2 Device 1 Device 2 Device 1 Device 2
Low QC 84 44–124 99.6 100.8 8.89 8.97 8.9 8.9 83–123 84–123
Mid QC 173 115–230 199.6 195.5 17.31 16.09 8.7 8.2 157–237 158–232
High QC 531 398–663 605.4 601.0 32.65 31.28 5.4 5.2 543–665 532–668
Creatinine units are mmol/L. Devices 1 and 2 are two separate Nova analyzers. Acceptable range is that stated by the manufacturer.
to eGFR has been actively promoted to fill a niche in the
POCT market. We evaluated the performance of this device
against the IDMS-aligned Roche enzymatic creatinine assay,
and assessed the potential use of the Nova device for detect-
ing silent kidney disease in the community. The results of
this study are also relevant for radiology patients using
potentially nephrotoxic contrast media (11) and in other
POCT environments.
Materials and methods
Ethics approval
Ethics approval to conduct this study was obtained from the Flinders
Clinical Research Ethics Committee (application number 222/08).
Patient samples
One hundred subjects (48 males and 52 females) participated in the
study; 63 were patients attending either the renal clinic or dialysis
clinic at the Renal Unit, Flinders Medical Centre (FMC), and 37
subjects were healthy volunteers.
Capillary whole blood specimens were obtained from each sub-
ject and immediately analyzed in singlicate with two Nova Stat-
Sensor creatinine devices using the same reagent strip lot number.
A venous whole blood specimen anticoagulated with lithium hep-
arin (Greiner blood tube, Greiner Labortechnik GmbH, Cat No
456083; Kremsmuenster, Austria) was obtained from each subject
at the same time and sent to the pathology laboratory at FMC,
Adelaide, South Australia. In the laboratory, the venous whole blood
sample was centrifuged (4500 g for 5 min) and a plasma sample
aliquoted for duplicate laboratory analysis.
Test method
The Nova Biomedical StatSensor creatinine meter measured creat-
inine in 1.2 mL of whole blood in 30 s. The sample was added to
a reagent strip which was inserted into the device prior to sample
application. In the reagent strip, creatinine is converted to hydrogen
peroxide in an enzymatic cascade involving creatininase, creatinase
and sarcosine oxidase. The signal generated from H2O2 was detected
amperometrically. Calibration was factory-encoded into the reagent
strip.
Fingerprick analyses were conducted according to manufacturer
directions by a non-laboratory operator trained by Nova Biomedical.
Comparison method
Creatinine was also measured in the laboratory by assaying plasma
from each patient in duplicate using the IDMS-aligned Roche Cre-
atinine Plus enzymatic assay (Cat No 1775685) with a Hitachi Mod-
ular P unit. The performance of this assay has been validated vs.
both the IDMS reference method and international reference mate-
rials (SRM 967) (12–15).
Imprecision
Imprecision (coefficient of variation, CV%) for creatinine measure-
ment on the Nova StatSensor device was assessed in three ways.
Within-run and day-to-day imprecision were calculated using
repeated analysis (ns10 and 20, respectively) of three levels of
Nova StatSensor quality control (QC) material (Cat No 43921-3;
QC lot numbers 5008340241, 5008100242 and 5008344243 for
within-day and 5009037241, 5009037242 and 5009043243 for day-
to-day). Between-device imprecision was calculated from the dif-
ference between results obtained on the same samples analyzed on
the two Nova devices wusing the equation ss6(Sd2/2n), where
ssstandard deviation, dsdifference between individual results on
the two devices and nsnumber of duplicates (98 in this data set)
and CV% ss/m=100 where ssstandard deviation and msmean
creatinine concentrationx.
Linearity
Linearity of the Nova analyzers was assessed by increasing the cre-
atinine concentration of a base pool of lithium heparin anticoagu-
lated venous whole blood (58 mmol/L) by 1000 mmol/L using a
concentrated solution of creatinine prepared from National Institute
of Standards and Technology Standard Reference Material (NIST
SRM) 914a (NIST, United States Department of Commerce). By
mixing the base pool and the spiked sample in various ratios, whole
blood samples were prepared in which the base pool was supple-
mented with 100, 250, 500, 750 and 1000 mmol/L of creatinine.
All samples were assayed with both Nova 1 and Nova 2 analyzers,
and linearity assessed using Clinical and Laboratory Standards Insti-
tute (CLSI) EP6-A guidelines (16) (see Statistical analyses).
Accuracy
The accuracy of creatinine results obtained with each Nova Stat-
Sensor device was compared to the mean of duplicate creatinine
results from the IDMS-aligned laboratory method using Passing-
Bablok linear regression analysis (17). Differences between results
were graphed against the Roche enzymatic assay using a modified
Bland-Altman difference plot (18).
eGFR on the Nova StatSensor, calculated automatically from the
measured creatinine using the modification of diet in renal disease
(MDRD) equation (factor 186), was also plotted against eGRF from
the laboratory method, calculated by the laboratory information sys-
tem (LIS) from the measured creatinine using the standardised
MDRD equation (factor 175). The ability of the Nova StatSensor
to correctly categorise eGFR above or below 60 mL/min was then
assessed by calculation of sensitivity, specificity, positive and neg-
ative predictive values.
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Figure 1 Plot showing differences between Nova StatSensor 1 and
IDMS-aligned laboratory Roche enzymatic creatinine results.
(A) Using the StatSensor factory encoded calibration. (B) Following
recalibration to align creatinine results to the Roche enzymatic
assay.
After alignment of the Nova StatSensor results to the laboratory
creatinine method, this process was repeated, now using an eGFR
factor of 175 for the Nova StatSensor.
Statistical analyses
Statistical analyses, including assessment of linearity, were per-
formed using the statistical package Analyse-it (clinical laboratory
version 2.21).
Results
Imprecision
Within-run and day-to-day imprecision averaged 3.3% and
8.9%, respectively at 100 mmol/L creatinine, and 2.8% and
5.3% at 600 mmol/L creatinine for the two StatSensor ana-
lyzers (Table 1). For the laboratory assay, year-long impre-
cision (approx. 1200 QC data points) was 1.9% and 1.4% at
similar low and high concentrations of creatinine. The impre-
cision of the Roche enzymatic assay was consistent with data
reported during the use of this method to develop the IDMS-
aligned 175 MDRD equation (14).
Between-device imprecision was 7.8% (all concentrations,
ns98), 7.8% for creatinine -150 mmol/L (ns62), and
6.2% for creatinine )150 mmol/L.
The StatSensor creatinine day-to-day imprecision did not
meet either the desirable or minimum analytical goal for
imprecision derived from biological variation criteria (CV
-2.2% and 3.2%, respectively) (19), or the criteria required
to keep the analytical error in eGFR calculations below 10%
(5). The laboratory assay met both these requirements.
Linearity
Minor deviations from linearity were observed and are
shown in parenthesis after the addition of 100 (–3.9%), 250
(5.4%), 500 (5.5%), 750 (2.0%) and 1000 (–3.3%) mmol/L
creatinine to a base pool of blood containing 58 mmol/L
creatinine. The CLSI EP6-A linearity protocol measures the
degree to which a curve (polynomial line of best fit) approx-
imates a straight line.
Initial method comparison
Creatinine concentrations in the samples tested ranged from
46 to 962 mmol/L by the laboratory method. Table 2 sum-
marises the method correlation statistics for the Nova
StatSensor device vs. the IDMS-aligned Roche enzymatic
method, split by creatinine concentration.
Using a factory-based calibration, StatSensor 1 (y) pro-
duced slightly lower results than the IDMS-aligned Roche
enzymatic assay (x) for 62 samples with creatinine concen-
trations -150 mmol/L (ys0.96x–3.5, average bias –7.3,
95% limits of agreement –36 toq21 mmol/L). For 100 sam-
ples spanning the full concentration range, the StatSensor
results were much lower (ys0.75xq10.2, average bias
–47.3, 95% limits of agreement –208 to q113 mmol/L).
Patients on dialysis had significantly lower StatSensor cre-
atinine results compared with the Roche enzymatic assay, as
shown in Figure 1A. Similar findings have been reported at
a recent conference (20–22), with interference from creatine
and urea described in one abstract (20), while the effect of
hemtocrit was ruled out as a cause of discordant results in
another study (21).
Because of the underestimation of creatinine, eGFR results
from StatSensor 1 were incorrectly categorised as )60
mL/min for 7/53 patients (false normal results). There were
no false abnormal results (eGFR -60 mL/min) (Figure 2A
and Table 3).
StatSensor 2 had very similar summary statistics, indicat-
ing a consistent factory calibration and analytical perform-
ance for the two instruments (ns98 pairs, average bias
between StatSensors 0.7 mmol/L, two samples had insuffi-
cient volume for assay on both devices). However, as illus-
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Figure 2 Plot of eGFR results (mL/min) from Nova StatSensor 1 vs. the laboratory Roche enzymatic method.
(A) Using the StatSensor factory encoded calibration. (B) Following recalibration to the Roche enzymatic assay.
trated in Figure 3, for individual samples, there was more
variation in results than expected between the two POC ana-
lyzers (95% limits of agreement –35 to q34 mmol/L for all
samples and –16 to q17 mmol/L for samples with labora-
tory creatinine -150 mmol/L).
Correction of observed method bias
Using the Passing-Bablok slope and intercept factors, the sig-
nificant overall negative bias observed across the full creat-
inine concentration range with the factory-calibrated Nova 1
device was corrected using a reciprocal recalibration equa-
tion: Nova (recalibrated)swNova (factory calibration)=
1.3333x – 13.53 mmol/L. Method comparison statistics post-
recalibration are provided in Table 2.
StatSensor 1 eGFR results were then recalculated using
the 175 MDRD equation and replotted against the IDMS-
aligned laboratory eGFR (Figure 2B). Once Nova StatSensor
1 was recalibrated to the laboratory assay, eGFR G60
mL/min was correctly identified vs. the laboratory assay for
37/47 patients (79%). There were 10 false abnormal results.
An eGFR -60 mL/min was identified correctly for 51/53
patients (96%). There were two false normal results (Table
3).
However, both before and after recalibration, we were
concerned by the number of StatSensor creatinine results
showing poor agreement with the laboratory method (Figure
1). Predialysis results from one patient were omitted from
graphs and statistical calculations because of very inconsis-
tent results (lab 541,538: Nova, factory calibration 186,154
mmol/L).
Discussion
Screening programs for early detection of CKD are increas-
ing important because the burden of the disease continues to
rise globally, and many risk factors, such as hypertension,
smoking and obesity can be readily modified (3). In the US,
the Kidney Early Evaluation Program (KEEP) provides such
a national screening agenda (23). As part of KEEP, creatinine
(and eGFR) is measured at a central laboratory and results
are returned to patients at a later date. POCT for creatinine
confers particular advantages for the CKD screening process
as participants can be provided with immediate feedback on
their kidney function during their community assessment. In
Australia, the recent KEY study combined POCT for creat-
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Table 3 Predictive values for Nova StatSensor vs. Roche Hitachi enzymatic assay using an eGFR cut-off value of 60 mL/min to detect
reduced kidney function.
Device Calibration Sensitivity, % Specificity, % PV (qve test), % PV (yve test), %
Nova 1 Factory calibration 86.8 100.0 100.0 87.0
Nova 2 Factory calibration 82.4 100.0 100.0 83.9
Nova 1 Post lab recalibration 96.2 78.7 83.6 94.9
Nova 2 Post lab recalibration 92.2 78.7 82.6 90.2
Positive test (reduced kidney function) eGFR -60 mL/min; negative test eGFR G60 mL/min.
Figure 3 Difference between creatinine results (mmol/L) on indi-
vidual patient samples, when measured on both Nova StatSensor
devices.
inine (and calculation of eGFR), glucose, hemoglobin A1c,
cholesterol, and urine albumin:creatinine ratio (ACR) with
family history, blood pressure and measurement of height,
weight and body mass index, as well as an exit interview
with a renal nurse to provide an integrated on-site approach
to targeted community-based CKD risk assessment (9).
POCT was considered pivotal to the success of KEY, with
)96% of participants stating POCT was convenient and
helped them understand their results better (9). In the KEY
study, creatinine was measured on an i-STAT device that
proved useful and robust in this setting. However, for large
scale risk assessment in settings such as pharmacies or work-
places, capillary whole blood is the sample of choice for
creatinine measurement.
The Nova StatSensor device, which is simple to use and
can measure creatinine using a fingerprick sample, has con-
siderable potential for use in this niche but its analytical
performance is of paramount importance in deciding its suit-
ability for screening. Based on the results of this evaluation,
agreement with laboratory creatinine results did not meet
expectations, especially using the factory-based calibration.
The device exhibited a significant negative bias at high cre-
atinine concentrations, with wide limits of agreement com-
pared to the well-established Roche enzymatic assay. The
reason for some unusual divergences from laboratory creat-
inine results and falsely low results for patients undergoing
dialysis requires further investigation. Imprecision (8.9%)
exceeded established criteria at creatinine concentrations
-150 mmol/L. For detecting eGFR -60 mL/min, the Nova
StatSensor recorded a 13% (7/53) false normal rate, meaning
these patients with stage 3 CKD would be missed.
Once Nova StatSensor 1 was recalibrated to the IDMS-
aligned Roche enzymatic Hitachi assay, the number of false
normal results decreased to 4% (2/53). However, 21% (10/
47) of results were now incorrectly classed as abnormal (i.e.,
eGFR -60 mL/min). For community-based programmes
and hospital use, we consider that with recalibration this
instrument will identify most patients with eGFR -60
mL/min, but there will be many falsely low eGFR results
that will require laboratory validation and contribute to
unnecessary stress among patients.
Throughout the evaluation period, some further problems
were experienced with the StatSensor method. These includ-
ed poor reproducibility with certain batches of QC material
(not used in the imprecision studies) and instability with dif-
ferent reagent strip lot numbers.
In summary, the Nova StatSensor did not measure creati-
nine as well as expected, and we believe that the assay needs
urgent improvement. Using the factory calibration, 18% of
creatinine results below 150 mmol/L differed by more than
20 mmol/L from the Roche enzymatic assay, and 62% of
results above 150 mmol/L differed by more than 20%. Many
samples had large differences in creatinine results compared
to the IDMS-aligned laboratory method (Figure 1); this is
concerning given international efforts to standardise creati-
nine results (5). Despite this, it could still be useful as a
screening test for CKD in community and other settings, as
the risk of missing CKD stage 3 with recalibration of the
instrument was -5% in this study.
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